Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies-Reference-Cited by-同舟云学术

Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies

Published:2016-02 Issue:2 Volume:35 Page:219-226
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Hwang Thomas J.¹,Kesselheim Aaron S.²

Affiliation:

1. Thomas J. Hwang is a venture capitalist at Bain Capital, in Boston, Massachusetts.

2. Aaron S. Kesselheim ( ) is an associate professor of medicine at Harvard Medical School, in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, in Boston.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference29 articles.

1. Estimated Economic Benefits During The ‘Decade Of Vaccines’ Include Treatment Savings, Gains In Labor Productivity

2. During The ‘Decade Of Vaccines,’ The Lives Of 6.4 Million Children Valued At $231 Billion Could Be Saved

3. Why We Don’t Have An HIV Vaccine, And How We Can Develop One

4. The Challenges Of Developing New Tuberculosis Vaccines

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative Strategies in Drug Discovery and Pharmacoinformatics;Recent Advances in Pharmaceutical Innovation and Research;2023

2. Willingness of Black and White Adults to Accept Vaccines in Development: An Exploratory Study Using National Survey Data;American Journal of Health Promotion;2020-12-28

3. An Analysis of Antibacterial Drug Development Trends in the United States, 1980–2019;Clinical Infectious Diseases;2020-06-25

4. Financing Vaccines for Global Health Security;2020-03-23

5. Innovation policy and the market for vaccines*;Journal of Law and the Biosciences;2020-01